A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Agents that promote the excretion of urine through their effects on kidney function.
Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.
An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
Conditional probability of exposure to a treatment given observed covariates.
The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% higher than blood urea nitrogen concentration because of the greater protein content of red blood cells. Increases in blood or serum urea nitrogen are referred to as azotemia and may have prerenal, renal, or postrenal causes. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
An amino acid that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as CREATININE in the urine.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. (1/35)

Although diuretics are recommended for the treatment of hypertension, decreased diuretic use and increased calcium antagonist use necessitate a comparison of the efficacy of these drugs in preventing cardiovascular events. Patients >/=60 years of age with systolic blood pressure of 160 to 220 mm Hg and diastolic blood pressure <115 mm Hg were enrolled. Patients were randomly assigned to 20 mg of sustained-release nicardipine hydrochloride twice daily or 2 mg of trichlormethiazide once daily by the double-dummy method and followed up for 5 years. A total of 414 patients were analyzed: 204 in the nicardipine group and 210 in the diuretic group. Blood pressure at entry was 172/94 mm Hg and 173/93 mm Hg, respectively, and decreased to 147/81 mm Hg and 147/79 mm Hg, respectively. Cardiovascular morbidity rates per 1000 persons per year were similar in the nicardipine and diuretic groups (27.8 and 26.8, respectively; P=0.923). The sex- and age-adjusted risk ratio for the nicardipine group was 0.973 (95% confidence interval, 0.514 to 1.839, P=0.932). The calcium antagonist and diuretic groups had a similarly decreased rate of cardiovascular events.  (+info)

Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. NICS-EH Study Group. National Intervention Cooperative Study in Elderly Hypertensives. (2/35)

We investigated the effect of long-term treatment with a calcium antagonist (nicardipine hydrochloride retard tablet) and a diuretic (trichlormethiazide) on quality of life (QOL) in elderly hypertensives in a multicenter, randomized, double-blind, comparative study (National Intervention Cooperative Study in Elderly Hypertensives Study Group). The percentage of patients who experienced side effects was 17.2% in the nicardipine group and 18.1% in the trichlormethiazide group and 2.9% and 4.3% of participants, respectively, withdrew due to those side effects. These results suggested that nicardipine was tolerated slightly better than trichlormethiazide. There were no significant differences between the two groups in terms of total QOL score or in degree of change (delta score) before and after calcium antagonist or diuretic administration. Lower score was seen in 3 categories (general symptoms, sleep scale, and sexual function) in the trichlormethiazide group (p< 0.05) and in one category (cognitive function) in the nicardipine group, but there was no significant difference in delta score in any of the individual items. In conclusion, the two anti-hypertensive agents had nearly equivalent effects on QOL in the long-term treatment of hypertension in the elderly and that neither resulted in a deterioration in QOL.  (+info)

The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients. (3/35)

Angiotensin-converting enzyme (ACE) inhibitors are known to be the most effective antihypertensive drugs for reducing left ventricular mass in hypertensives when compared to other classes of drugs. In the present study, we evaluated the effects of imidapril, an ACE inhibitor, on serum procollagen type III amino-terminal peptide (PIIIP) levels as well as the left ventricular mass index (LVMI). The subjects consisted of 15 patients (12 men and 3 women) in the outpatient clinic of our hospital who were diagnosed as essential hypertensives and who had not been treated with any antihypertensive medication prior to the study. Left ventricular hypertrophy was observed in all of the patients, ie., LVMI >110 g/m2 in men and >106 g/m2 in women. Blood pressure, LVMI, and serum PIIIP levels were measured before and after treatment with imidapril for 6 months. The starting dose of imidapril was 5 mg, and this was increased to 10 mg. Finally, 1 mg of trichlormethiazide was added to obtain adequate control of blood pressure. Blood pressure significantly decreased in 12 patients, and the mean LVMI decreased significantly from 153.1 +/- 9.0 to 135.4 +/- 6.3 (p< 0.01) after treatment. The changes in LVMI and PIIIP levels with treatment had significant correlation (r=0.639, p< 0.05). The present study showed that imidapril reduces the left ventricular mass in hypertensives after 6 months of treatment, and that this may at least in part be due to a decrease in the collagen content of the hypertrophied heart, suggesting that serum PIIIP levels are a useful marker of the regression of left ventricular hypertrophy.  (+info)

Effects of antihypertensive treatment on platelet function in essential hypertension. (4/35)

To evaluate the effect of antihypertensive therapy on platelet activation in essential hypertension, the plasma levels of beta-thromboglobulin (beta-TG) were examined in 45 patients with essential hypertension and 20 age-matched normotensive control subjects. Hypertensive patients were assigned to monotherapy with one of five different antihypertensive drugs for 6 months, and the change of plasma levels of beta-TG was reexamined after the completion of the monotherapy. The plasma beta-TG increased in hypertensive patients compared with levels in normotensive control subjects. Monotherapy with each drug resulted in sufficient blood pressure control in all hypertensive patients. The plasma beta-TG decreased significantly after monotherapy with an alpha-blocker or an angiotensin-converting enzyme inhibitor (ACEI). The plasma beta-TG increased with the use of a diuretic but did not change with the use of a beta-blocker or calcium antagonist. The platelet activation observed in patients with essential hypertension is reversed by monotherapy with an alpha-blocker or an ACEI. It is possible that these drugs reduce the development of hypertensive vascular complications due to suppression of platelet activation in patients with essential hypertension.  (+info)

Comparison of long-term therapeutic effect of an ACE inhibitor, temocapril, with that of a diuretic on microalbuminuria in non-diabetic essential hypertension. (5/35)

Many investigators have reported that angiotensin-converting enzyme (ACE) inhibitors have antiproteinuric effects and retard the progression of renal impairment in diabetic patients. On the other hand, those effects of ACE inhibitors have not been well established in patients with essential hypertension. This study was conducted to prospectively evaluate whether an ACE inhibitor, temocapril, could modify the urinary microalbumin excretion rate (UAE) in hypertensive outpatients who had no signs of renal impairment. To compare the long-term effect of temocapril with that of a diuretic on UAE, hypertensive patients treated with a diuretic (trichlormethiazide) were enrolled in a prospective study if they had normal serum creatinine levels and no overt proteinuria during a 3-month screening period. A urinary microalbumin-to-urinary-creatinine ratio (mg albumin/mmol Cr) was used as an estimate of UAE. Patients visited the hospital monthly to determine blood pressure (BP) and UAE. After baseline observation during the treatment with the diuretic, the subjects were randomly divided into two groups. In group A, the diuretic was switched to temocapril, 2 to 4 mg once daily for 12 months. In group B, the subjects continued to receive the diuretic for an additional 12 months. Seventy-six outpatients (41 men and 35 women; mean age, 59.0+/-1.4 years) with essential hypertension entered the study. The effects of temocapril on BP appeared to be clinically similar to those of the trichlormethiazide, but the use of temocapril significantly decreased UAE. In group A (n=37), UAE decreased significantly (p<0.01) from the baseline value of 4.19+/-0.37 mg albumin/mmol Cr to 2.47+/-0.29 and 2.68+/-0.28 mg albumin/mmol Cr at the 6th and 12th month of temocapril therapy, respectively. In contrast, in group B (n=39) UAE was unchanged (baseline, 4.16+/-0.63 mg albumin/mmol Cr; 6 months, 4.92+/-0.72; 12 months, 4.71+/-0.74). These results indicate that long-term therapy with temocapril may be superior in reducing UAE than is diuretic therapy in patients with essential hypertension who had no signs of renal impairment.  (+info)

Tolerability and safety of a calcium channel blocker in comparison with a diuretic in the treatment of elderly patients with hypertension: secondary analysis of the NICS-EH. (6/35)

A randomized prospective controlled study, the National Interventional Cooperative Study in Elderly Hypertensives (NICS-EH), previously demonstrated that the preventive effect of the long-acting calcium channel blocker nicardipine on the cardiovascular endpoint was similar to that of the diuretic, trichlormethiazide. The present report is a sub-analysis in which we compare the tolerability and safety of the calcium channel blocker with that of a diuretic in the long-term treatment of elderly hypertensives. A total of 429 elderly patients with hypertension were assigned to the nicardipine group or the diuretic group by the double-dummy method and were followed up for 5 years. Two hundred four patients in the nicardipine group and 210 patients in the diuretic group were analyzed. The incidences of fatal and nonfatal cardiovascular (CV) events in the two groups were comparable, and there was no significant difference in the cumulative event-free rate. However, the total incidence of adverse reactions, including non-CV events and unfavorable BP changes, was 31 cases (15.2%) in the nicardipine group, which was significantly lower than the 47 cases (22.4%) in the diuretic group (log-rank: p=0.026, G. Wilcoxon: p=0.01). The total number of medical endpoints, including CV events, the withdrawal of the patient from the study, was 52 (25.5%) in the nicardipine group, which was significantly lower than the 65 (31.0%) in the diuretic group (log-rank: p=0.078, G. Wilcoxon: p=0.044). It was concluded that sustained-release nicardipine is better tolerated, as it exhibits a lower incidence of medical-related withdrawals such as adverse drug reactions, non-cardiovascular events and unfavorable BP responses during the treatment.  (+info)

A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide. (7/35)

Exercise-induced acute renal failure (ARF) developed in a 45-year-old man during antihypertensive therapy with losartan and trichlormethiazide. The antihypertensive therapy was stopped and marked hypouricemia became apparent during improvement of his renal function. The daily urinary excretion of uric acid was normal and an increased fractional excretion of uric acid was observed. Renal biopsy revealed that the kidney was recovering from acute tubular necrosis with interstitial fibrosis. Based on the results of pyrazinamide and benzbromarone tests, we classified this case as one of presecretory reabsorption defect of uric acid. Antihypertesive therapy with benidipine and candesartan was initiated, and the patient has not had any ARF episodes since. Because idiopathic renal hypouricemia can be associated with exercise-induced ARF and chronic renal dysfunction, careful antihypertensive therapy and follow-up evaluation of renal function might be necessary for hypertensive patients with idiopathic renal hypouricemia.  (+info)

Clinical experience with an oral diuretic, trichlormethiazide. (8/35)

The main objective of this study was to observe the long-term effects of the administration of trichlormethiazide on the urine and blood. Fourteen patients suffering from essential hypertension or edema requiring diuretic therapy were treated for periods of one to 12 months (mean 5.4 months). There were no significant changes in urine values, blood counts, or serum sodium or potassium levels. Additional nitrogen retention occurred in two patients with renal failure, but no significant changes in blood urea nitrogen occurred in the remainder. Serum uric acid levels were lower at the end of treatment than before. The blood pressure fell in nine patients. No toxic effects were observed.  (+info)

Trichlormethiazide is a thiazide diuretic drug, which is primarily used to treat hypertension (high blood pressure) and edema (fluid retention) associated with various medical conditions such as heart failure, kidney disease, or liver cirrhosis. It works by increasing the excretion of salt and water from the body through urine, thereby reducing fluid volume and lowering blood pressure.

The medical definition of Trichlormethiazide is:

A potent long-acting oral thiazide diuretic with a chlorothiazide side chain at position 2 and trichloromethyl group at position 6 of the benzothiadiazine ring. It has a longer duration of action than other thiazides, making it suitable for once-daily dosing in the management of hypertension and edema. Its diuretic effect is mainly due to inhibition of sodium reabsorption in the distal convoluted tubule of the kidney, leading to increased excretion of water and electrolytes (particularly sodium and chloride ions) in the urine.

Trichlormethiazide is available under various brand names, such as Metahydrin, Naqua, and Diuril Sodium. It should be used with caution and under medical supervision due to potential side effects like electrolyte imbalance, dehydration, hypotension, and impaired glucose tolerance.

Diuretics are a type of medication that increase the production of urine and help the body eliminate excess fluid and salt. They work by interfering with the reabsorption of sodium in the kidney tubules, which in turn causes more water to be excreted from the body. Diuretics are commonly used to treat conditions such as high blood pressure, heart failure, liver cirrhosis, and kidney disease. There are several types of diuretics, including loop diuretics, thiazide diuretics, potassium-sparing diuretics, and osmotic diuretics, each with its own mechanism of action and potential side effects. It is important to use diuretics under the guidance of a healthcare professional, as they can interact with other medications and have an impact on electrolyte balance in the body.

Hypokalemia is a medical condition characterized by abnormally low potassium levels in the blood, specifically when the concentration falls below 3.5 milliequivalents per liter (mEq/L). Potassium is an essential electrolyte that helps regulate heart function, nerve signals, and muscle contractions.

Hypokalemia can result from various factors, including inadequate potassium intake, increased potassium loss through the urine or gastrointestinal tract, or shifts of potassium between body compartments. Common causes include diuretic use, vomiting, diarrhea, certain medications, kidney diseases, and hormonal imbalances.

Mild hypokalemia may not cause noticeable symptoms but can still affect the proper functioning of muscles and nerves. More severe cases can lead to muscle weakness, fatigue, cramps, paralysis, heart rhythm abnormalities, and in rare instances, respiratory failure or cardiac arrest. Treatment typically involves addressing the underlying cause and replenishing potassium levels through oral or intravenous (IV) supplementation, depending on the severity of the condition.

Sodium chloride symporter inhibitors are a class of pharmaceutical agents that block the function of the sodium chloride symporter (NCC), which is a protein found in the kidney's distal convoluted tubule. The NCC is responsible for reabsorbing sodium and chloride ions from the filtrate back into the bloodstream, helping to regulate electrolyte balance and blood pressure.

Sodium chloride symporter inhibitors work by selectively binding to and blocking the NCC, preventing it from transporting sodium and chloride ions across the cell membrane. This leads to increased excretion of sodium and chloride in the urine, which can help lower blood pressure in patients with hypertension.

Examples of sodium chloride symporter inhibitors include thiazide diuretics such as hydrochlorothiazide and chlorthalidone, which have been used for many years to treat hypertension and edema associated with heart failure and liver cirrhosis. These medications work by reducing the amount of sodium and fluid in the body, which helps lower blood pressure and reduce swelling.

It's worth noting that while sodium chloride symporter inhibitors can be effective at treating hypertension, they can also cause side effects such as electrolyte imbalances, dehydration, and increased urination. As with any medication, it's important to use them under the guidance of a healthcare provider and to follow dosing instructions carefully.

Uric acid is a chemical compound that is formed when the body breaks down purines, which are substances that are found naturally in certain foods such as steak, organ meats and seafood, as well as in our own cells. After purines are broken down, they turn into uric acid and then get excreted from the body in the urine.

However, if there is too much uric acid in the body, it can lead to a condition called hyperuricemia. High levels of uric acid can cause gout, which is a type of arthritis that causes painful swelling and inflammation in the joints, especially in the big toe. Uric acid can also form crystals that can collect in the kidneys and lead to kidney stones.

It's important for individuals with gout or recurrent kidney stones to monitor their uric acid levels and follow a treatment plan prescribed by their healthcare provider, which may include medications to lower uric acid levels and dietary modifications.

Hyperuricemia is a medical condition characterized by an excessively high level of uric acid in the blood. Uric acid is a waste product that's produced when the body breaks down purines, which are substances found in certain foods and drinks, such as red meat, seafood, and alcoholic beverages. Normally, uric acid is dissolved in the blood and then excreted by the kidneys through urine. However, if there's too much uric acid in the body or if the kidneys can't eliminate it efficiently, it can build up in the blood, leading to hyperuricemia.

Mild cases of hyperuricemia may not cause any symptoms and may not require treatment. However, high levels of uric acid can lead to the formation of uric acid crystals, which can accumulate in the joints and tissues, causing inflammation and pain. This condition is known as gout. Hyperuricemia can also increase the risk of developing kidney stones and kidney disease.

Hyperuricemia can be caused by several factors, including a diet high in purines, genetic factors, kidney disease, certain medications, and conditions that cause rapid cell turnover, such as cancer or psoriasis. Treatment for hyperuricemia typically involves lifestyle changes, such as reducing the intake of purine-rich foods and beverages, maintaining a healthy weight, and staying hydrated. Medications may also be prescribed to lower uric acid levels in the blood and prevent gout attacks.

Furosemide is a loop diuretic medication that is primarily used to treat edema (fluid retention) associated with various medical conditions such as heart failure, liver cirrhosis, and kidney disease. It works by inhibiting the sodium-potassium-chloride cotransporter in the ascending loop of Henle in the kidneys, thereby promoting the excretion of water, sodium, and chloride ions. This increased urine output helps reduce fluid accumulation in the body and lower blood pressure.

Furosemide is also known by its brand names Lasix and Frusid. It can be administered orally or intravenously, depending on the patient's condition and the desired rate of diuresis. Common side effects include dehydration, electrolyte imbalances, hearing loss (in high doses), and increased blood sugar levels.

It is essential to monitor kidney function, electrolyte levels, and fluid balance while using furosemide to minimize potential adverse effects and ensure appropriate treatment.

A propensity score is a statistical concept used in epidemiology and biostatistics to reduce bias and confounding in observational studies. It is a predicted probability of being exposed to a certain treatment or intervention, based on a set of observed covariates or characteristics.

The propensity score is calculated by estimating the probability of exposure (i.e., treatment or intervention) for each individual in the study sample, using logistic regression or other statistical models. The resulting scores are then used to match individuals with similar propensities for exposure, creating a balanced comparison group that more closely resembles a randomized controlled trial.

Propensity score methods can help to account for confounding variables and improve the internal validity of observational studies, making them a useful tool in medical research where randomized controlled trials may not be feasible or ethical. However, it is important to note that propensity score matching is not a panacea and has its own limitations, such as the potential for unmeasured confounding and the need for sufficient sample size.

Blood Urea Nitrogen (BUN) is a laboratory value that measures the amount of urea nitrogen in the blood. Urea nitrogen is a waste product that is formed when proteins are broken down in the liver. The kidneys filter urea nitrogen from the blood and excrete it as urine.

A high BUN level may indicate impaired kidney function, as the kidneys are not effectively removing urea nitrogen from the blood. However, BUN levels can also be affected by other factors such as dehydration, heart failure, or gastrointestinal bleeding. Therefore, BUN should be interpreted in conjunction with other laboratory values and clinical findings.

The normal range for BUN is typically between 7-20 mg/dL (milligrams per deciliter) or 2.5-7.1 mmol/L (millimoles per liter), but the reference range may vary depending on the laboratory.

Creatine is a organic acid that is produced naturally in the liver, kidneys and pancreas. It is also found in small amounts in certain foods such as meat and fish. The chemical formula for creatine is C4H9N3O2. In the body, creatine is converted into creatine phosphate, which is used to help produce energy during high-intensity exercise, such as weightlifting or sprinting.

Creatine can also be taken as a dietary supplement, in the form of creatine monohydrate, with the goal of increasing muscle creatine and phosphocreatine levels, which may improve athletic performance and help with muscle growth. However, it is important to note that while some studies have found that creatine supplementation can improve exercise performance and muscle mass in certain populations, others have not found significant benefits.

Creatine supplements are generally considered safe when used as directed, but they can cause side effects such as weight gain, stomach discomfort, and muscle cramps in some people. It is always recommended to consult a healthcare professional before starting any new supplement regimen.

Antihypertensive agents are a class of medications used to treat high blood pressure (hypertension). They work by reducing the force and rate of heart contractions, dilating blood vessels, or altering neurohormonal activation to lower blood pressure. Examples include diuretics, beta blockers, ACE inhibitors, ARBs, calcium channel blockers, and direct vasodilators. These medications may be used alone or in combination to achieve optimal blood pressure control.

In addition, trichlormethiazide increases the excretion of potassium. Trichlormethiazide appears to block the active ... As a diuretic (in particular a thiazide), trichlormethiazide encourages water loss from the body. Trichlormethiazide works by ... "DrugBank: DB01021 (Trichlormethiazide)". DrugBank. Retrieved 2008-01-23. "Trichlormethiazide and Dexamethasone for veterinary ... Although trichlormethiazide is used to treat hypertension, its hypotensive effects may not necessarily be due to its role as a ...
"Trichlormethiazide and Dexamethasone for veterinary use". Wedgewood Pharmacy. Archived from the original on 12 December 2007. ... It can also be combined with trichlormethiazide to treat horses with swelling of distal limbs and general bruising. ...
... and trichlormethiazide. Bumetanide is a loop diuretic (water pill) that prevents your body from absorbing too much salt, ...
... in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide ...
... trichlormethiazide MeSH D03.438.174.285 - cyclopenthiazide MeSH D03.438.174.300 - diazoxide MeSH D03.438.174.475 - ...
... trichlormethiazide MeSH D02.886.655.500.285 - cyclopenthiazide MeSH D02.886.655.500.300 - diazoxide MeSH D02.886.655.500.475 - ... trichlormethiazide MeSH D02.886.590.700.135.285 - cyclopenthiazide MeSH D02.886.590.700.135.300 - diazoxide MeSH D02.886. ...
Trichlorex Trichlormas trichlormethiazide (INN) trichlormethine (INN) triciribine (INN) triclabendazole (INN) triclacetamol ( ...
... and potassium C03AB04 Chlorothiazide and potassium C03AB05 Polythiazide and potassium C03AB06 Trichlormethiazide and potassium ... C03DB01 Amiloride C03DB02 Triamterene C03EA01 Hydrochlorothiazide and potassium-sparing agents C03EA02 Trichlormethiazide and ... C03AA02 Hydroflumethiazide C03AA03 Hydrochlorothiazide C03AA04 Chlorothiazide C03AA05 Polythiazide C03AA06 Trichlormethiazide ... C03AA07 Cyclopenthiazide C03AA08 Methyclothiazide C03AA09 Cyclothiazide C03AA13 Mebutizide QC03AA56 Trichlormethiazide, ...
In addition, trichlormethiazide increases the excretion of potassium. Trichlormethiazide appears to block the active ... As a diuretic (in particular a thiazide), trichlormethiazide encourages water loss from the body. Trichlormethiazide works by ... "DrugBank: DB01021 (Trichlormethiazide)". DrugBank. Retrieved 2008-01-23. "Trichlormethiazide and Dexamethasone for veterinary ... Although trichlormethiazide is used to treat hypertension, its hypotensive effects may not necessarily be due to its role as a ...
Acute intermittent porphyria (AIP) is one of the porphyrias, a group of diseases involving defects in heme metabolism and that results in excessive secretion of porphyrins and porphyrin precursors. AIP manifests itself by abdomen pain, neuropathies, and constipation, but, unlike most types of porphyria, patients with AIP do not have a rash.
Detailed drug Information for Lisdexamfetamine dimesylate. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
Detailed drug Information for Acnex Topical. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
The antihistamine in this medicine will add to the effects of alcohol and other central nervous system (CNS) depressants (medicines that slow down the nervous system, possibly causing drowsiness). Some examples of CNS depressants are other antihistamines or medicine for hay fever, other allergies, or colds; sedatives, tranquilizers, or sleeping medicine; prescription pain medicine or narcotics; barbiturates; medicine for seizures; muscle relaxants; or anesthetics, including some dental anesthetics. Check with your doctor before taking any of the above while you are taking this medicine.. Also, stomach problems may be more likely to occur if you drink alcoholic beverages while taking a medicine that contains aspirin. In addition, drinking large amounts of alcoholic beverages while taking a medicine that contains acetaminophen may cause liver damage.. The antihistamine in this medicine may cause some people to become drowsy, dizzy, or less alert than they are normally. Make sure you know how you ...
The drug information on TRICHLORMETHIAZIDE include structure, IUPAC, physiochemical properties, synthesis, SAR, MOA, ... Trichlormethiazide Physical Appearance, Trichlormethiazide SAR, Trichlormethiazide Solubility, Trichlormethiazide Synthesis, ... Mcq on trichlormethiazide a Thiazide diuretic drug, Medicinal Uses of trichlormethiazide, Side Effects of trichlormethiazide, ... Trichlormethiazide Chemical Property, Trichlormethiazide Melting Point, Trichlormethiazide Molecular Weight, ...
Trichlormethiazide. Back to List. Back to Top. 10. Tetracyclines (antibiotics, anti-infectives) - examples:. ...
Acute intermittent porphyria (AIP) is one of the porphyrias, a group of diseases involving defects in heme metabolism and that results in excessive secretion of porphyrins and porphyrin precursors. AIP manifests itself by abdomen pain, neuropathies, and constipation, but, unlike most types of porphyria, patients with AIP do not have a rash.
Thus, the IC50 values of hOAT1 for hydrochlorothiazide, trichlormethiazide, and acetazolamide are approximately 25, 100, and 2 ... Diuretics tested were thiazides, including chlorothiazide, cyclothiazide, hydrochlorothiazide, and trichlormethiazide; loop ...
Consecutive administration of trichlormethiazide in rats fed a low-sodium diet resulted in marked diuresis, body weight loss, ... clearance studies were performed using rats treated with furosemide and trichlormethiazide.. Acute administration of test ...
Consecutive administration of trichlormethiazide in rats fed a low-sodium diet resulted in marked diuresis, body weight loss, ... clearance studies were performed using rats treated with furosemide and trichlormethiazide.. Acute administration of test ...
It fit into our low-dose category based on the starting dose of 1 mg of trichlormethiazide, although the article did not ...
Trichlormethiazide. approved, vet_approved. unknown. inhibitor. Details. DB00869. Dorzolamide. approved. yes. inhibitor. ...
Trichlormethiazide. CAS Registry Number®. 133-67-5 Discover more in SciFindern. Cite this Page. . CAS Common Chemistry. CAS, a ...
Trichlormethiazide. CAT#: 318904 CAS#: 133-67-5 Trichlormethiazide is a diuretic with properties similar to those of ...
Trichlormethiazide 50 = Tussi-Organidin 52 = Tylox 45 = Unipres 49 = Valium 49 = Vistaril 53 = Vitality plus stress vitamin ...
Pretium officinas trichlormethiazide CAS Number.... 123456Next ,>> Page 1 / 16 ...
Pharmaceutical Intermediate API Trichlormethiazide Powder CA....... *. High Quality Iron Door Hinge (B-5030- 2BB ). ...
De Fabréck Präis Trichlormethiazide CAS Zuel .... * China Fournisseur Fourniture Furosemid CAS Nummer 54-.... ...
Trichlormethiazide, Tricitrates, Tricodene, Tricodene Forte, Tricodene NN, Tricodene Pediatric, Tricodene Sugar-Free, Tricom, ...
Hereditary coproporphyria is one of the porphyrias, a group of diseases that involves defects in heme metabolism and that results in excessive secretion of porphyrins and porphyrin precursors. Inheritance is autosomal (usually autosomal dominant, but sometimes autosomal recessive).
Acute intermittent porphyria (AIP) is one of the porphyrias, a group of diseases involving defects in heme metabolism and that results in excessive secretion of porphyrins and porphyrin precursors. AIP manifests itself by abdomen pain, neuropathies, and constipation, but, unlike most types of porphyria, patients with AIP do not have a rash.
METAHYDRIN Trichlormethiazide * MICROZIDE Hydrochlorothiazide, HCTZ1 discussion * NAQUA Trichlormethiazide * NIAZIDE ...
Trichlormethiazide. Aside from these drugs, the NBA also banned the use of marijuana and cocaine. The NBA wanted to make the ...
Cập nhật thông tin Top #10 Thuốc La Marlboro Flavor Code xem nhiều nhất, mới nhất 10/2023. Thông tin, hình ảnh, video clip về Thuốc La Marlboro Flavor Code mới nhất. Đề xuất thông tin liên quan đến Thuốc La Marlboro Flavor Code nhanh nhất và mới nhất.
Trichlormethiazide. Dacomitinib. M. Enoximone. Telbivudine. Cefditoren. Dasatinib. Bicisate. V. Entacapone. Tipiracil. ...
  • Trichlormethiazide (INN, currently being sold under the brand names of Achletin, Diu-Hydrin and Triflumen) is a diuretic with properties similar to those of hydrochlorothiazide. (wikipedia.org)
  • Trichlormethiazide is a diuretic with properties similar to those of hydrochlorothiazide. (medkoo.com)
  • In order to evaluate the decrease of uric acid excretion as the cause of diuretic-induced hyperuricemia in experimental animals, clearance studies were performed using rats treated with furosemide and trichlormethiazide. (go.jp)
  • As a diuretic (in particular a thiazide), trichlormethiazide encourages water loss from the body. (wikipedia.org)
  • In addition, trichlormethiazide increases the excretion of potassium. (wikipedia.org)
  • Trichlormethiazide prevents active chloride reabsorption at the early distal tubule through the sodium chloride contransportor which results in an increase in the excretion of sodium, chloride and water from the body. (gpatindia.com)
  • The conditioning factor in this product, to be used to closebefore the race is the time of excretion of the Trichlormethiazide. (firsthorsevetcare.com)
  • Depending on accumulation in blood and other factors, an application of Trichlormethiazide may delay excretion between 12 and 36 hours. (firsthorsevetcare.com)
  • If is used only in a "low dose application" (without having used Trichlormethiazide before, the week before the race) it´s possible to minimize the excretion times until 12 hours before the Race. (firsthorsevetcare.com)
  • Trichlormethiazide works by inhibiting Na+/Cl− ion reabsorption from the distal tubules of the kidneys. (wikipedia.org)
  • Trichlormethiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle. (wikipedia.org)
  • Although trichlormethiazide is used to treat hypertension, its hypotensive effects may not necessarily be due to its role as a diuretic. (wikipedia.org)
  • In veterinary medicine, trichlormethiazide can be combined with dexamethasone to be used on horses with mild swelling of distal limbs and general bruising. (wikipedia.org)
  • Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. (tohoku.ac.jp)
  • Therefore, we studied the effect on intracellular Mg2+, Na+ and K+ concentrations of a thiazide diuretic (trichlormethiazide 4 mg/d) in red blood cells of 14 patients with mild essential hypertension, and of a combination of a thiazide diuretic and a potassium-sparing diuretic (trichlormethiazide and amiloride 2 mg/d each) in red blood cells of 11 patients with mild essential hypertension. (nih.gov)
  • No information is available on the amount of trichlormethiazide in breastmilk. (nih.gov)
  • Although trichlormethiazide is used to treat hypertension, its hypotensive effects may not necessarily be due to its role as a diuretic. (wikipedia.org)
  • 10) who randomly received antihypertensive therapy with or without trichlormethiazide for 12 weeks. (cdc.gov)